Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation

Molecular Medicine

Volumn 15, Issue 3-4, 2009, Pages 70-75

  Bruchfeld, Annette ^a   Carrero, Juan J ^b   Qureshi, Abdul R ^b   Lindholm, Bengt ^b   Barany, Peter ^a   Heimburger, Olof ^a   Hu, Maowen ^c   Lin, Xinchun ^c   Stenvinkel, Peter ^a   Miller, Edmund J ^c,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; CHRONIC KIDNEY FAILURE; ENDOTHELIUM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ENDOTHELIUM; HUMANS; INFLAMMATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC;

EID: 64549151549     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2008.00109     Document Type: Article

References (26)

1. Stenvinkel P, et al. (2005) IL-10, IL-6, and TNF- alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 67:1216-33.
2. Avesani CM, et al. (2006) Inflammation and wasting in chronic kidney disease: partners in crime. Kidney Int. Suppl. 70:S8-S13.
3. Panichi V, et al. (2004) Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial. Trans-plant. 19:1154-60.
4. Honda H, et al. (2006) Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney Dis. 47:139-48.
5. Foley RN, Parfrey PS, Sarnak MJ. (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32(5 Suppl 3): S112-9.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351:1296-305.
7. David JR. (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U. S. A. 56:72-7.
8. Zernecke A, Bernhagen J, Weber C. (2008) Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 117:1594-602.
9. Morand EF. (2005) New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern. Med. J. 35:419-26.
10. Alexander Schmeisser, et al. (2005) The expression of macrophage migration inhibitory factor 1a (MIF 1α) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis 178:83-94.
11. Yao-Zhong Kong, et al. (2005) Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 178:207-15.
12. Anke Burger-Kentischer, et al. (2006) Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 184:28-38.
13. Schober A, et al. (2004) Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109:380-5.
14. Becker H, et al. (2006) Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin. Rheumatol. 4:1-5.
15. Brown FG, et al. (2001) Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Transplantation. 71:1777-83.
16. Stenvinkel P, et al. (1999) Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 55:1899-911.
17. Descamps-Latscha B, et al. (1995) Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J. Immunol. 154:882-92.
18. Pecoits-Filho R, et al. (2003) Associations between circulating inflammatory markers and residual renal function in CRF patients. Am. J. Kidney Dis. 41:1212-8.
19. Bruchfeld A, et al. (2008) High Mobility Group Box Protein-1 correlates with renal function in Chronic Kidney Disease (CKD). Mol. Med. 14:109-15.
20. Zaza G, et al. (2008) Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrol. Dial. Transplant. 23:1673-81.
21. Thompson A, Danesh J. (2006) Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J. Intern. Med. 259:481-92.
22. McQueen MJ, et al. (2008) INTERHEART study investigators. Lipids, lipoproteins, and apolipo-proteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372:224-33.
23. Wijbrandts CA, et al. (2008). Sustained changes in lipid profile and macrophage migration inhibitory factor (MIF) levels after anti-TNF therapy in rheumatoid arthritis. Ann. Rheum. Dis. 2008, Aug 22. [Epub ahead of print]
24. Radstake TR, et al. (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 52:3020-9.
25. Sanchez-Niño MD,et al. (2008) The MIF receptor CD74 in diabetic podocyte injury. J. Am. Soc. Nephrol. 2008 Oct 8. [Epub ahead of print]
26. Stenvinkel P, Pecoits-Filho R, Lindholm B. (2003) Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J. Am.Soc. Nephrol. 14:1927-39.